雜志介紹

Translational Lung Cancer Research雜志介紹

《Translational Lung Cancer Research》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱轉(zhuǎn)化肺癌研究，本刊主要出版、報道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為4，最新CiteScore 指數(shù)為7.2。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Case report: targeted sequencing improves the diagnosis of multiple synchronous lung cancers

  Author: Ba, Yufeng; Li, Haomiao; Zhu, Jianping; Wang, Haoran; Lv, Hongwei; Guo, Chongqing; Sun, Rui; Zheng, Jiawen; Meng, Lin; Shi, Shanshan

• Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA

  Author: Ling, Xiaodong; Zhang, Luquan; Fang, Chengyuan; Liang, Hao; Zhu, Jinhong; Ma, Jianqun

• Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101)

  Author: Wang, Rong; Shi, Meiqi; Ji, Mei; Han, Zhengxiang; Chen, Lingxiang; Liu, Yong; Lu, Kaihua; Liu, Lianke; Chen, Bi; Zhang, Xizhi; Miao, Liyun; Shu, Yongqian

• Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis

  Author: Zhang, Mai; Huang, Qian; Yu, Min; Xue, Jianxin; Huang, Meijuan; Lu, You; Zhang, Yan

英文介紹

Translational Lung Cancer Research雜志英文介紹

Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.